It is well known that exposure to one antigen can modulate the immune responses that develop following exposure to closely related antigens. It is also known that the composition of the repertoire can be skewed to favor epitopes shared between a current infection and a preceding one, a phenomenon referred to as "original antigenic sin." It was of interest, therefore, to investigate the antibody response that develops following exposure to the malaria vaccine candidate homologue Plasmodium yoelii MSP1 19 in mice that had previously experienced malaria infection and vice versa. In this study, preexposure of mice to Plasmodium yoelii elicited native anti-MSP1 19 antibody responses, which could be boosted by vaccination with recombinant MSP1 19 . Likewise, infection of MSP1 19 -primed mice with P. yoelii led to an increase of anti-MSP1 19 antibodies. However, this increase was at the expense of antibodies to parasite determinants other than MSP1 19 . This change in the balance of antibody specificities significantly affected the ability of mice to withstand a subsequent infection. These data have particular relevance to the possible outcome of malaria vaccination for those situations where the vaccine response is suboptimal and suggest that suboptimal vaccination may in fact render the ultimate acquisition of natural immunity more difficult.
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The 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 (MSP1 19 ) is a leading malaria vaccine candidate (reviewed in reference 6). Immunization of monkeys (11, 12) or mice (1, 8) with recombinant MSP1 19 confers protection against challenge infection. Studies using mouse models have clearly shown that immunity induced by MSP1 19 immunization is dependent on specific antibodies (Abs) present at the time of challenge (1, 7, 8) and requires an active immune response postchallenge involving B cells and CD4 ϩ T cells (9) . An ideal malaria vaccine should effectively induce protective immunity in both naive individuals and those populations living in areas of endemicity. Therefore, immune responses generated in response to vaccination in both naive and exposed individuals should be considered in studies to develop a malaria vaccine. While MSP1 19 has been shown to be a promising malaria vaccine candidate, we have found that CD4 ϩ T cells specific to a helper epitope on MSP1 19 are deleted via apoptosis during malaria infection (18) . As a result, spleen cells from infected mice respond to parasite antigens significantly less than spleen cells from uninfected mice. This may reflect the situation in humans, where antigen-specific immune responses are suppressed during Plasmodium falciparum infection (10) . It is important, therefore, to assess vaccine efficacy in individuals previously exposed. Conversely, it is important to consider the impact of vaccination on the subsequent ability of the parasite to interact with the immune system and consequently generate both MSP1 19 specific Abs and Abs specific for other parasite antigens which may contribute in a significant way to the ultimate development of immunity. Francis (4) and Fazekas de St Groth (3) reported almost 50 years ago that prior exposure to one strain of an organism could skew the immune response to subsequent strains toward those antigenic determinants that are shared between the strains at the expense of novel determinants expressed on the new strain. The term "original antigenic sin" was coined to describe this phenomenon. We were interested to explore whether malaria subunit vaccination might prevent the development of protective Abs specific for those antigens other than the subunit vaccine, and if so, to determine the mechanism of the effect.
The experiments in this study were thus designed to model in the mouse those situations where malaria-preexposed individuals receive vaccination and also where vaccinated individuals from a nonmalaria area might travel to regions with malaria transmission.
MATERIALS AND METHODS
Experimental animals and parasites. Six-to 8-week-old female BALB/c and B10.S mice were purchased from Animal Resources Center, Willeton, Australia. Plasmodium yoelii YM (lethal strain) and Plasmodium chabaudi were used.
Immunization protocol. To investigate the effectiveness of MSP1 19 vaccination in malaria-preexposed animals, groups of BALB/c mice were infected with P. yoelii YM and were then treated daily 4 days later with three consecutive doses of 0.2 mg/ml pyrimethamine. This procedure is referred to as infection/cure. Three weeks later, all mice were vaccinated with phosphate-buffered saline (PBS) or 20 g MSP1 19 formulated in complete Freund's adjuvant (CFA) (Sigma, St Louis, MO). Control groups consisted of mice that were not infected but were vaccinated with the same dose of antigens (Table 1 ). Five weeks after vaccination, mice were challenged intravenously with 10 4 P. yoelii YM-parasitized red blood cells (RBC). Vaccination of preexposed mice is hereafter referred to as protocol 1.
To examine the effect of malaria infection on vaccinated animals, groups of BALB/c mice were immunized with PBS or 20 g MSP1 19 formulated in CFA. Three weeks later, mice were subjected to an infection/cure or were revaccinated with 20 g MSP1 19 (Table 2 ). All mice, including control groups, were given the same curative dose of pyrimethamine. Five weeks after the last immunization, mice were challenged intravenously with 10 4 P. yoelii YM-parasitized RBC. Exposure of prevaccinated mice to an infection/cure or vaccination with MSP1 19 is hereafter referred to as protocol 2.
Determination of Ab responses. Blood samples were taken from each individual mouse on the same day prior to each infection or vaccination. Levels of Abs in sera were determined by enzyme-linked immunosorbent assay (ELISA) as described previously (8) . Briefly, Maxisorb immunoplates (Nalge Nunc International, NY) were coated overnight at 4°C with 100 l of 0.3-g/ml MSP1 19 or 10-g/ml crude parasite antigens. After three washes with 0.05% Tween-PBS, wells were blocked with 200 l of 1% bovine serum albumin (BSA) (Sigma, St. Louis, MO) in PBS and incubated for 1 h at 37°C. Supernatants were discarded, and 100 l of serial dilutions of sera in 1% BSA in Tween-PBS was added. After incubation at 37°C for 1 h, wells were washed and 100 l of a 1:3,000 dilution of horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin G (Silenus, Australia) was added. After incubation at 37°C for 1 h, wells were washed, 100 l of substrate solution (2,2-azino-di-[ethyl-benzithiozolin sulfonate]; Sigma) was added, and wells were incubated at room temperature for 30 min. The absorbance was read at 405 nm.
Statistical analysis. Comparisons among experimental groups by Student's t test were performed using a statistical analysis program of Sigma Plot. The levels of peak parasitemia were compared among experimental groups. Significance was set at a P value of Ͻ0.05.
RESULTS
Ab responses following vaccination in P. yoelii-exposed mice. The first set of experiments was performed to determine whether prior exposure to P. yoelii affected the ability of mice to respond to MSP1 19 vaccination. Sera were collected at different time points, and Ab responses to MSP1 19 or crude P. yoelii parasite antigens were determined. Sera taken prior to any experiments did not contain Abs specific to MSP1 19 or P. yoelii antigens (data not shown). Mice that had been exposed to P. yoelii infection/cure are referred to as P. yoelii exposed. Mice that had not received an infection followed by drug cure are referred to as nonexposed. Sera taken prior to MSP1 19 immunization or PBS immunization are referred to as preimmunization sera, whereas sera taken after immunization or after infection/cure are referred to as postimmunization or postinfection sera, respectively.
The level of Abs against MSP1 19 or whole parasite antigens in P. yoelii-exposed mice did not change significantly after PBS immunization ( Fig. 1C and G). P. yoelii-exposed mice had developed low levels of anti-MSP1 19 Abs before MSP1 19 boosting, and the levels of the Abs increased after boosting but did not differ from those for nonexposed animals that received MSP1 19 immunization (Fig. 1B versus D) . Boosting with MSP1 19 had no effect on the level of anti-P. yoelii Abs in P. yoelii-exposed mice (Fig. 1H ). There was no effect of treatment on the distribution of the isotype of the MSP1 19 -specific Abs (Fig. 2 ).
The data demonstrate that exposure to P. yoelii elicits an Ab response to MSP1 19 which could be boosted by MSP1 19 vaccination and that prior exposure to P. yoelii did not affect the Ab response to vaccination with MSP1 19 .
Ab responses following infection of MSP1 19 -vaccinated animals. Mice were given a single injection of MSP1 19 or PBS in CFA as described in Materials and Methods (protocol 2). Infection/cure of PBS-immunized mice only slightly enhanced the levels of Abs against MSP1 19 (Fig. 3A) . Sera from mice that had been primed with MSP1 19 contained Abs to the antigen, with levels of Abs increasing further following either an infection/cure (Fig. 3B ) or MSP1 19 boosting (Fig. 3C) . Levels of Ab against P. yoelii increased in all groups following infection/cure or MSP1 19 boosting (Fig. 3D to F) . These data show that exposure to P. yoelii resulted in an increase in Ab response to MSP1 19 .
The distribution of the MSP1 19 -specific Ab isotypes of MSP1 19 -primed mice that were boosted by an infection/cure was similar to that for mice receiving a second MSP1 19 vaccination (Fig. 4) .
Protection against challenge infection. Five weeks after the last immunization of the above groups, all mice were challenged with 10 4 P. yoelii YM-parasitized RBC. Parasitemia was then monitored. Figure 5 shows levels of parasitemia for mice that received the different protocols of immunization. Nonexposed mice that were given PBS succumbed to the infection within 7 days (Fig. 5A ). All five nonexposed mice given a single immunization dose with MSP1 19 developed parasitemia; two animals died, and three were able to eliminate parasites (Fig.  5B ). It should be noted, however, that mice given a full MSP1 19 vaccination schedule (four doses of MSP1 19 ) are completely protected (8) ; that protocol was not followed here so as to monitor and compare the effects of prior P. yoelii exposure and P. yoelii-exposed mice that were immunized with PBS were able to control parasite growth, with only one animal showing a peak of 0.01% parasitemia on day 8 (Fig. 5C ). Vaccination of P. yoelii-exposed animals with MSP1 19 also conferred protection, although two of five animals developed parasitemia with peaks of 0.02 and 3.8% (geometric mean peak parasitemia: 0.04%) (Fig. 5D) .
PBS-immunized mice that were subsequently given an infection/cure developed patent parasitemia (geometric mean peak parasitemia: 0.21%) but were able to control parasite growth (Fig. 5E ). All five MSP1 19 -vaccinated mice that were given an infection/cure also showed patent parasitemia during the challenge infection (geometric mean peak parasitemia: 1.65%) (Fig. 5F ). One of five mice that had been vaccinated with two doses of MSP1 19 died by day 9 postchallenge (Fig. 5G) ; one had no detectable parasitemia, and three animals showed patent parasitemia.
Mice which received MSP1 19 vaccination prior to infection/ cure (protocol 2) (Fig. 5F ) developed a mean peak parasitemia significantly higher than that developed by mice that received infection/cure prior to MSP1 19 vaccination (protocol 1) (geometric mean peak parasitemia of 1.65% versus 0.04%; P Ͻ 0.05).
Prior vaccination with MSP1 19 impeded the ability of mice to produce Abs to other determinants on the parasite. We were concerned that prior exposure to MSP1 19 -CFA or, to a lesser extent, PBS-CFA might alter the ability of parasite exposure to induce robust immunity. Since immunity induced by prior exposure to P. yoelii is believed to be mediated primarily by Abs (8), we asked whether prior vaccination with MSP1 19 impeded the ability of mice to generate an Ab response to other determinants on the parasite. Sera from MSP1 19 -vaccinated P. yoelii-infected mice (from Fig. 5F ) were tested in an inhibition ELISA in which free MSP1 19 was premixed with sera to absorb MSP1 19 -specific Abs. The sera were then tested for their ability to recognize MSP1 19 and whole P yoelii parasites. The results (Fig. 6 ) demonstrate that free MSP1 19 can effectively block MSP1 19 -specific Abs from recognizing MSP1 19 (Fig. 6B) . However, there was also a significant reduction in the ability of the sera to respond to P. yoelii when the sera were blocked with free MSP1 19 (Fig. 6D) . By comparison, MSP1 19 -blocked sera from mice that had not been exposed to MSP1 19 but had been exposed to P. yoelii infection did not significantly affect Ab binding to P yoelii antigens at any of the serum dilutions tested (1/300 to 1/2,400) (Fig. 6C) . These data are consistent with the reduced protection seen when P. yoelii-exposed mice were previously exposed to MSP1 19 (Fig. 5E versus F 19 . Impaired protective immunity was exclusively induced by the suboptimal vaccination of a particular antigen. To confirm that the impaired protective immunity in MSP1 19 -primed mice (Fig. 5F ) was indeed induced by prior exposure to MSP1 19 antigen, a similar experimental approach was performed with B10.S mice. Because B10.S mice do not respond to MSP1 19 (14, 16) , we expected that this approach would not affect the protective immunity following MSP1 19 priming and boosting by infection/cure. As shown in Fig. 7a , similar to the mice that were exposed to an infection/cure and boosted with MSP1 19 (7a, E), MSP1 19 -primed B10.S mice that were boosted with an infection/cure were completely protected against parasite challenge (7a, D). We have previously reported the immune response to MSP1 19 in B10.S mice in extensive detail (14) . These mice were unable to produce anti-MSP1 19 Abs and developed high parasitemia after infection.
Because MSP1 19 used in this experiment was derived from P. yoelii, this suboptimal vaccination should not affect the protective immunity induced by exposure to other species of parasites. As expected, the MSP1 19 -primed BALB/c mice that had been given an infection/cure with P. chabaudi parasites had a level of parasitemia following challenge similar to that of mice that received an infection/cure followed by boosting with MSP1 19 when challenged with P. chabaudi (Fig. 7b, D versus  E) . To further confirm that the impaired protective immunity induced by the suboptimal vaccination was exclusively due to the immune responses to antibody production, a T-cell epitope (18) from MSP1 19 (peptide 24 [p24], EPTPNAYYEGVFC SSS) (18) was also used in this study. p24 priming had no ability to alter the level of protection, as shown in Fig. 7c, D . Collectively, the data demonstrate that an impaired protective immune response was induced by the suboptimal vaccination with MSP1 19 .
DISCUSSION
The benefit of a malaria vaccine is dependent on its effectiveness in preventing disease and death. In developing a malaria vaccine for universal use, it is important to understand the The aims of this study were to investigate the immune responses that develop following MSP1 19 vaccination in malariapreexposed animals and vice versa. Anti-MSP1 19 Abs could be detected in prevaccination sera from malaria-preexposed mice ( Fig. 1 C and D) , indicating that P. yoelii infection elicits a natural albeit limited Ab response to MSP1 19 . MSP1 19 vaccination of these preexposed mice resulted in a boosting of the MSP1 19 -specific Ab response (Fig. 1D ), but this increase of anti-MSP1 19 Abs was not accompanied by an increase of antiwhole-parasite Abs (Fig. 1H) . We have previously reported that malaria infection results in deletion of adoptively transferred MSP1 19 -specific Th1 cells (18) and memory B cells (19) . The increase in MSP1 19 -specific antibodies seen in this study suggests that infection had not resulted in deletion of MSP1 19 specific helper cells to such an extent as to ablate helper activity. We also observed that infection of MSP1 19 -primed mice with P. yoelii led to an increase of anti-MSP1 19 Abs (Fig. 3B) . Boosting of P. yoelii-exposed mice with MSP1 19 or infection/ cure of MSP1 19 -primed mice boosted Ab responses to MSP1 19 in both groups to comparable levels ( Fig. 1D versus 3B) .
However, MSP1 19 boosting of malaria-preexposed mice (Fig. 5D ) and infection/cure of MSP1 19 -primed mice (Fig. 5F ) induced different degrees of protective immunity against P. yoelii challenge. The levels of anti-MSP1 19 Abs in these groups were equivalent (Fig. 1D versus 3B ). This suggested that immune responses other than MSP1 19 -specific Abs were responsible for the differences in protection. This conclusion was confirmed from the study of the malaria-preexposed, PBSvaccinated group. This group demonstrated the highest degree of protection (Fig. 5C ), but they had low levels of anti-MSP1 19 -specific Abs (Fig. 1C) ; although they had levels of wholeparasite-specific Abs comparable to those in the poorly protected malaria-preexposed, MSP1 19 -boosted mice ( Fig. 1G and  3E ), the component of those Abs that were not directed against MSP1 19 was significantly greater in the malaria-preexposed, PBS-vaccinated group than in the malaria-preexposed, MSP1 19 -boosted group, as shown by ELISA inhibition studies using free MSP1 19 (Fig. 6) . Significantly, in this study, we have shown that the impaired protective immunity in the MSP1 19 -primed mice was at least in part induced by suboptimal vaccination with this antigen. The evidence comes from three separate sets of experiments. First, MSP1 19 -nonresponding B10.S mice were used to test whether the MSP1 19 suboptimal vaccine affects immunity induced by homologous parasite infection/cure. We could demonstrate no such effect in MSP1 19 -nonresponding mice, as the data showed that MSP1 19 -primed B10.S mice that were boosted with an infection/cure had the same level of protection to parasite challenge (7a, D) as mice that were primed with infection/cure and boosted with MSP1 19 (7a, E). Second, we tested whether P. yoelii-derived-MSP1 19 priming affects immunity induced by a different species of parasite. As shown in Fig. 7b, D and E, the P. yoelii-derived-MSP1 19 -primed BALB/c mice given an infection/cure with P. chabaudi parasites had the same level of protective immunity to P. chabaudi as mice that had been primed with infection/cure and boosted with P. yoelii-derived MSP1 19 . Finally, a single P. yoelii-derived-MSP1 19 Tcell epitope was used to prime BALB/c mice. We showed that p24 priming had no ability to skew the immune response (Fig. 7c) . Taken together, these experiments suggested that the impaired protective immunity that follows suboptimal vaccination was induced by the immune responses to P. yoelii-derived MSP1 19 . These results have profound implications for a human vaccine program in a situation where the vaccine response may be suboptimal for a variety of reasons. Suboptimal vaccination may render the ultimate acquisition of immunity that follows parasite exposure more difficult. This study shows that a single injection of MSP1 19 impedes the development of natural immunity that arises following parasite infection. The MSP1 19 vaccination regimen in this study was deliberately suboptimal in order to more clearly reflect the likely situation in humans, where some will respond well to vaccination but others less well. Exposure of MSP1 19 -primed mice to P. yoelii resulted in an increase of anti-MSP1 19 Abs, suggesting that MSP1 19 is a dominant B-cell epitope and that malaria infection induces the boosting of a preexisting Ab response. However, the increase of anti-MSP1 19 Abs observed in these mice did not confer protection at the same level as that observed in mice exposed to malaria parasites before MSP1 19 vaccination. It is well known that in rodent systems a very high titer of anti-MSP1 19 antibodies is required for protection and that in these situations no mice demonstrate a patent parasitemia following challenge (8) . However, when the immune response to vaccination is suboptimal, mice are not protected (8) . This study now demonstrates that not only are mice not protected by a low-titer Ab response but also that they can be inhibited from developing an otherwise protective immune response to the parasite. This "original antigenic sin" phenomenon has also been observed in humans, in which malaria infection selectively induces existing Ab responses to immunodominant epitopes (5, 15, 17) , but its contribution to protection remains to be investigated.
Similar to the findings in this study, a previous study has shown that immunization of preimmune Saimiri sciureus monkeys with recombinant proteins associated with the membranes of trophozoite-and schizont-infected erythrocytes results in an enhancement of Ab responses and better protective immunity (13) . In another study (2) , prior exposure of Aotus vociferans monkeys to P. falciparum primes the production of anti-native MSP1 19 Abs, which are further boosted by vaccination with recombinant MSP1 19 . This monkey demonstrated better protection than a vaccinated malaria-naive monkey (2), analogous to the results of this study (Fig. 5) . However, the effect of prior exposure to MSP1 19 on the ability to induce immunity following parasite exposure has been studied to only a very limited degree. In the study referred to above (2) six of six monkeys that were vaccinated with MSP1 19 and infected were protected against a second challenge infection. However, the MSP1 19 vaccine regimen was highly efficacious by itself in that seven of nine monkeys in total were protected from high parasitemia during their initial challenge. Our study was designed to assess the effect of suboptimal vaccination.
In conclusion, this study demonstrates that (i) prior exposure to malaria does not seem to have negative effect on the response to subunit vaccination and (ii) vaccination with a partially effective subunit vaccine may impair subsequent development of immunity following malaria infection. Potential differences in response to vaccines between naive and semiimmune or preexposed individuals should be taken into consideration when planning malaria vaccine trials, and the consequences of a less-than-optimal vaccination in naive individuals should be considered. The need for optimal vaccine-induced Ab responses should be considered with respect to the overall development of malaria immunity.
